Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Metamizole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metamizole SCHEMBL24996 | 0.78 | ALOX15 (1.00) | KDM4EALOX15MAPTALOX12PTGS1 | |
| Metamizole SCHEMBL1825291 | 0.77 | ALOX15 (0.97) | KDM4EALOX15MAPTALOX12PTGS1 | |
| Metamizole SCHEMBL24995 | 0.77 | ALOX15 (0.97) | KDM4EALOX15MAPTALOX12PTGS1 | |
| Metamizole SCHEMBL28278546 | 0.76 | ALOX15 (0.95) | KDM4EALOX15MAPTALOX12PTGS1 | |
| Emorfazone SCHEMBL26203 | 0.75 | BRD4 (0.46) | KDM4EPTGS1LMNABRD4BRD9 | |
| Metamizole SCHEMBL17331306 | 0.71 | ALOX15 (0.83) | KDM4EALOX15MAPTALOX12PTGS1 | |
| Metamizole SCHEMBL27722368 | 0.69 | MAPT (0.59) | KDM4EALOX15MAPTALOX12PTGS1 | |
| Metamizole SCHEMBL934309 | 0.68 | ALOX15 (0.77) | KDM4EALOX15MAPTALOX12PTGS1 | |
| Moricizine SCHEMBL20771178 | 0.68 | CYP3A4 (0.67) | KDM4EALOX15MAPTALOX12PTGS1 | |
| Metamizole SCHEMBL24997 | 0.66 | PTGS1 (1.00) | KDM4EALOX15MAPTALOX12PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291644-B2 | Indole derivatives | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-7153852-B2 | Indole compounds, process for producing the same and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-12-26 | — | — | US | disclosed |
| US-7135495-B2 | Indole derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-11-14 | — | — | US | disclosed |
| US-20060194864-A1 | Indole derivatives | ONO PHARMACEUTICAL CO., LTD. | 2006-08-31 | — | — | US | disclosed |
| US-20050004097-A1 | Indole derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| US-20050004096-A1 | Indole derivatives, process for producing the same and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| US-20040198831-A1 | Remedial agent for arthrosis deformans | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-10-07 | — | — | US | disclosed |
| EP-1424325-A1 | INDOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| EP-1424335-A1 | INDOLE DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| EP-1421934-A1 | REMEDIAL AGENT FOR ARTHROSIS DEFORMANS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194864-A1 | Indole derivatives | IDO1, IDO2, PTGIR | PTGS1 21/4885KDM4E 3234/4885ALOX15 580/4885 |
| US-20050004097-A1 | Indole derivatives | IDO1, IDO2, PTGIR | PTGS1 21/4885KDM4E 3234/4885ALOX15 580/4885 |
| US-20050004096-A1 | Indole derivatives, process for producing the same and drugs containing the same as the active ingredient | IDO1, IDO2, PTGIR | PTGS1 18/4885KDM4E 2671/4885ALOX15 418/4885 |
| US-20040198831-A1 | Remedial agent for arthrosis deformans | MMP1, MMP3, MMP11 | PTGS1 33/4885KDM4E 3850/4885ALOX15 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.